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Abstract: Endothelial dysfunction is a major clinical problem affecting virtually every 
patient requiring critical care. Volatile anesthetics are frequently used during the 
perioperative period and protect the heart and kidney against ischemia and reperfusion 
injury. We aimed to determine whether isoflurane, the most commonly used volatile 
anesthetic in the USA, protects against endothelial apoptosis and necrosis and the 
mechanisms involved in this protection. Human endothelial EA.hy926 cells were 
pretreated with isoflurane or carrier gas (95% room air + 5% CO2) then subjected to 
apoptosis with tumor necrosis factor-α or to necrosis with hydrogen peroxide. DNA 
laddering and in situ Terminal Deoxynucleotidyl Transferase Biotin-dUTP Nick-End 
Labeling (TUNEL) staining determined EA.hy926 cell apoptosis and percent LDH 
released determined necrosis. We also determined whether isoflurane modulates the 
expression and activity of sphingosine kinase-1 (SK1) and induces the phosphorylation of 
extracellular signal regulated kinase (ERK MAPK) as both enzymes are known to protect 
against cell death. Isoflurane pretreatment significantly decreased apoptosis in EA.hy926 
cells as evidenced by reduced TUNEL staining and DNA laddering without affecting 
necrosis. Mechanistically, isoflurane induces the phosphorylation of ERK MAPK and 
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increased SK1 expression and activity in EA.hy926 cells. Finally, selective blockade of 
SK1 (with SKI-II) or S1P1 receptor (with W146) abolished the anti-apoptotic effects of 
isoflurane. Taken together, we demonstrate that isoflurane, in addition to its potent 
analgesic and anesthetic properties, protects against endothelial apoptosis most likely via SK1 
and ERK MAPK activation. Our findings have significant clinical implication for protection of 
endothelial cells during the perioperative period and patients requiring critical care. 
Keywords: EA.hy926; sphingosine kinase; extracellular signal-regulated kinase; necrosis; 
volatile anesthetic 
 
1. Introduction 
The integrity and viability of the vascular endothelium are essential for homeostasis of all vital 
organs. The endothelium provides a semi-permeable barrier for selective exchange of nutrients and 
fluids [1]. Furthermore, endothelial cells produce several critically important compounds including 
nitric oxide, sphingosine 1-phosphate (S1P) and prostaglandins, which not only regulate blood supply 
but also produce cytoprotection in many disease states including systemic inflammatory response 
syndrome and ischemia and reperfusion [1,2]. Clinically, endothelial dysfunction is a major problem in 
critical care medicine and during the perioperative period [3]. Furthermore, endothelial cell 
dysfunction plays a major role in many acute and chronic human diseases including ischemia and 
reperfusion injury, coronary artery disease, diabetes mellitus and systemic inflammatory response 
syndrome [1,3].  
Volatile anesthetics are administered to virtually all patients subjected to general anesthesia and are 
an integral part of the perioperative period. Volatile anesthetics including isoflurane have non-anesthetic 
effects including effects on blood pressure, heart rate and systemic vascular resistance [4]. In addition, 
we previously reported that volatile anesthetics protected against renal ischemia reperfusion injury  
in vivo and had direct anti-inflammatory and anti-necrotic effects in cultured human kidney proximal 
tubule (HK-2) cells in vitro [5]. The initial anti-inflammatory mechanisms involve plasma membrane 
phosphatidylserine externalization with subsequent release of a potent anti-inflammatory cytokine 
TGF-β1 [5]. Furthermore, most volatile anesthetics are lipophilic molecules and have been shown to 
increase membrane fluidity and activate sphingomyelin hydrolysis [6]. The lysophospholipid S1P in 
particular is a product of sphingomyelin hydrolysis and functions as both an extracellular ligand for 
specific G protein coupled receptors as well as an intracellular second messenger in promoting cell 
growth, survival and reduction of apoptosis [7]. After inhalation, volatile anesthetics are first taken up 
by the circulatory system and endothelial cells are rapidly exposed; therefore the interactions between 
endothelial cells and volatile anesthetics are of great interest [8,9]. 
In this study we examined whether isoflurane reduces endothelial cell death due to necrosis or 
apoptosis and elucidated the mechanisms of isoflurane mediated endothelial cell protection. We test 
the hypothesis that isoflurane reduces endothelial apoptosis and necrosis via phosphorylation of 
extracellular signal-regulated kinase (ERK MAPK) and via induction of sphingosine kinase 1 (SK1) to 
increase production of a well characterized cytoprotective signaling molecule S1P [7,10]. Int. J. Mol. Sci. 2012, 13 979 
 
2. Results and Discussion 
2.1. Isoflurane Pretreatment Reduces Apoptosis in EA.hy926 Cells Exposed to TNF-α 
Human endothelial EA.hy926 cells exposed to carrier gas for 16 hours did not display any 
appreciable TUNEL staining (Figure 1A and 1E). Cells exposed to carrier gas for 16 hours followed 
by TNF-α 20 ng/mL for 48 hours showed significantly increased TUNEL positive cells (Figure 1B and 
1E). EA.hy926 cells pretreated with isoflurane and then exposed to TNF-α 20 ng/mL for 48 hours 
showed ~6.7 fold (p < 0.05) reduction in TUNEL positive apoptotic cells when compared to cells 
exposed to carrier gas and TNF-α (Figure 1D and 1E).  
Figure 1. Representative TUNEL staining images (200×, representative of 4 independent 
experiments) demonstrate that isoflurane decreases EA.hy926 cell apoptosis induced by 
TNF-α. EA.hy926 cell were pretreated with either carrier gas (A,B) or isoflurane at 2.5% 
(2 MAC) isoflurane (C,D) for 16 hours. Subsequently, EA.hy926 cells were treated with 
either vehicle (saline, A,C) or with TNF-α 20 ng/mL for 48 hours (B,D). Enlarged image in 
B shows characteristic apoptotic cells with fragmented nuclei. The percentage of TUNEL 
positive cells were quantified as shown in E. n = 4 per group. * p < 0.05 vs. carrier gas 
group. 
# p < 0.05 vs. carrier gas + TNF-α. Data presented as mean ± SEM. 
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Figure 1. Cont.  
 
Eight hour isoflurane pretreatment also reduced the number of TUNEL positive apoptotic cells 
(data not shown). Similarly, EA.hy926 cells exposed to carrier gas for 8-16 hours did not display any 
appreciable DNA laddering. Cells exposed to carrier gas for 16 hours followed by TNF-α 20 ng/mL 
for 48 hours showed an increase in DNA laddering (Figure 2, representative of 4 independent 
experiments). Cells pretreated with isoflurane then exposed to TNF-α 20 ng/mL for 48 hours showed 
decreased DNA laddering when compared to cells exposed to carrier gas and TNF-α (Figure 2). 
Figure 2. Representative DNA laddering images demonstrating reduced apoptosis in 
EA.hy926 cells with treatment with isoflurane (2.5% for 16 hours) followed by exposure to 
TNF-α (20 ng/mL for 48 hours) when compared to treatment with carrier gas followed by 
TNF-α. Representative of 4 independent experiments. 
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2.2. Isoflurane Does not Protect Against H2O2-Induced Necrosis in EA.hy926 Cells 
After treatment with isoflurane or carrier gas, there were no significant differences in necrosis 
induced with 2 mM H2O2 between carrier gas (LDH released at 8 hours after 8 hours pretreatment =  
29.4 ± 2.6%, n = 4) and isoflurane (LDH released at 8 hours after 8 hours pretreatment = 28.3 ± 2.5%,  
n = 4, p = 0.65) treated groups. Similarly, there were no significant differences at any other time points 
(2–12 hours, data not shown). 
2.3. Isoflurane Treatment Phosphorylates ERK MAPK to Induce of SK1 
EA.hy926 cells pretreated with isoflurane (2.5% or 2 MAC) for 2–4 hours show increased 
phosphorylation of ERK MAPK when compared to EA.hy926 cells exposed to carrier gas (Figure 3,  
4 hour pretreatment with isoflurane shown).  
Figure 3. Isoflurane increases ERK MAPK phosphorylation in EA.hy926 cells without 
changing total ERK expression. (A) Representative immunoblotting images of β-actin, 
phosphorylated ERK and total ERK from 4 independent experiments; (B) Densitometric 
quantifications of band intensities relative to beta-actin. n = 4 per group. * p < 0.05 vs. 
carrier gas group. Cells were treated with either carrier gas or with 2.5% isoflurane in 
carrier gas for 4 hours. 
 
In addition, EA.hy926 cells exposed to isoflurane (2.5% or 2 MAC) for 3-6 hours show increased 
SK1 mRNA when compared to cells exposed to carrier gas (Figure 4, 6 hour exposure shown). Cells 
treated with isoflurane also showed an increase in SK1 protein expression (Figure 5, 16 hour exposure 
shown). In contrast to SK1, treatment of cells with isoflurane did not increase mRNA or protein 
expression for SK2 (Figure 4 and Figure 5). Int. J. Mol. Sci. 2012, 13 982 
 
Figure 4. Isoflurane treatment selectively increases sphingosine kinase-1 (SK1) mRNA 
expression in EA.hy926 cells. (A) Representative RT-PCR images for GAPDH, SK1 and 
SK2 from 4 independent experiments; (B) Densitometric quantifications of band intensities 
for SK1 and SK2 relative to GAPDH from RTPCR reactions. n = 4 per group. * p < 0.05 
vs. carrier gas group. Cells were exposed to either carrier gas or isoflurane 2.5% (2 MAC) 
for 6 hours. 
 
Figure 5. Isoflurane treatment selectively increases sphingosine kinase-1 (SK1) protein 
expression in EA.hy926 cells. (A) Representative immunoblotting images for β-actin, SK1 
and SK2 from 4 independent experiments; (B) Densitometric quantifications of band 
intensities relative to β-actin. n = 4 per group. * p < 0.05 vs. carrier gas group. Cells were 
exposed to either carrier gas or isoflurane 2.5% or 2 MAC for 16 hours. 
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Finally, inhibition of ERK MAPK phosphorylation with a selective MEK1 inhibitor (PD98059) 
significantly reduced isoflurane-mediated (2.5% for 3 hours) induction of SK1 mRNA in EA.hy926 
human endothelial cells (Figure 6). 
Figure 6. Inhibition of ERK MAPK phosphorylation with PD98059 (a selective MEK1 
inhibitor) significantly reduced isoflurane-mediated induction of SK1 mRNA in EA.hy926 
human endothelial cells. (A) Representative RT-PCR images for GAPDH, SK1 and SK2 
from 4 independent experiments; (B) Densitometric quantifications of band intensities for 
SK1 and SK2 relative to GAPDH from RTPCR reactions. n = 4 per group. * p < 0.05 vs. 
carrier gas group. 
# p < 0.05 vs isoflurane+vehicle group. Cells were exposed to either 
carrier gas or isoflurane 2.5% (2 MAC) for 3 hours. 
 
2.4. SK or S1P1 Receptor Inhibition Prevents Isoflurane-Mediated Reduction in Apoptosis 
Figure 7 (TUNEL staining) shows that a selective SK inhibitor (SKI-II) or a selective S1P1 receptor 
antagonist (W146) reversed the protective effects of isoflurane (2.5% for 8 hours) against TNF-α 
induced apoptosis (induced with 24 hours of 20 ng/mL TNF-α treatment). Propidium iodide nuclear 
stain (lower panel) was performed to demonstrate equivalent cell number among experimental groups. 
DNA laddering assay also showed that SKI-II blocked the anti-apoptotic effects of isoflurane 
treatment (data not shown). Int. J. Mol. Sci. 2012, 13 984 
 
Figure 7. Inhibition of sphingosine kinase prevents isoflurane-mediated reduction in 
apoptosis. Representative TUNEL staining images (200×, representative of 4 independent 
experiments) demonstrate that SKI-II, a potent SK inhibitor, or W146, a selective S1P1 
receptor antagonist, attenuates isoflurane-mediated reduction in TUNEL positive apoptotic 
cells. EA.hy926 cells were pretreated with 2 MAC isoflurane for 8 hours and apoptosis 
induced by 8 hour treatment with 20 ng/mL TNF-α. Propidium iodide nuclear stain was 
also performed to demonstrate equivalent cell number among experimental groups. 
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2.5. Isoflurane Increases SK Activity and S1P Formation in EA.hy926 Cells 
Isoflurane treated EA.hy926 cells had demonstrated 1.27 + 0.07 fold higher SK activity compared 
to carrier gas treated cells (n = 4, p < 0.01). HPLC analysis for S1P showed increased S1P synthesis in 
EA.hy926 cells treated with isoflurane (1.27 + 0.04 fold, n = 6, p < 0.001) compared to the carrier gas 
treated group. 
2.6. Discussion 
Volatile anesthetics are one of the most widely used drugs in the USA during the perioperative 
period. In addition to its analgesic and anesthetic properties, they are well known to have powerful 
non-anesthetic properties. For example, several of the clinically utilized volatile anesthetics have 
negative inotropic effects, decrease systemic vascular resistance and venous return [4]. Furthermore, 
volatile anesthetics have cytoprotective properties in several cell types. For example, several clinically 
utilized volatile anesthetics including isoflurane precondition the myocardium against ischemia and 
reperfusion injury [11]. We have previously demonstrated that isoflurane as well as sevoflurane 
produces powerful anti-necrotic and anti-inflammatory effects in renal proximal tubule cells in vivo 
and in vitro [5,12,13]. Harnessing these non-anesthetic properties of volatile anesthetics may have 
important clinical implications for critically ill patients anesthetized in the OR and sedated in the ICU.  
We determined whether isoflurane reduces apoptosis or necrosis in EA.hy926 cells. Apoptosis and 
necrosis are two major pathways of cell death [14]. Apoptosis occurs in a pre-programmed and energy 
dependent manner involving activation of several cysteine proteases called caspases. These caspases 
initiate a complex cascade of events which lead to DNA fragmentation and cell death. Necrosis, 
however, is thought to be a passive, non-energy dependent process characterized by rapid cell swelling 
(oncosis), mitochondrial changes and eventual cell lysis with release of the cytoplasmic contents into 
the interstitial surroundings causing the recruitment of inflammatory cells [14]. 
In this study, we show that isoflurane selectively inhibited TNF-α induced apoptosis in EA.hy926 
cells. Previous studies demonstrated volatile anesthetic-mediated protection against endothelial cell 
death although the exact mechanisms of protection were not fully elucidated. Isoflurane has been 
shown to decrease ICAM-1, VCAM and NF-κB expression [15] and reduces cytokine-induced 
apoptosis via protein kinase C activation [8] as well as by modulating mitochondrial ATP-sensitive 
potassium channels [16]. We demonstrate lack of protection against necrosis in EA.hy926 cells. This is 
in contrast to previous studies that showed anti-necrotic effects of isoflurane in renal epithelial   
cells [13] and in aortic endothelial cells [9]. The effects of isoflurane may be tissue specific as 
isoflurane reduced cell death in aortic endothelial cells but had no effect on pulmonary artery 
endothelial cells after H2O2 treatment [9]. Taken together, isoflurane most likely modulates diverse 
anti-apoptotic and anti-necrotic signaling pathways in a tissue and cell death specific manner. 
One of the limitations of our model of necrosis is the concentration of H2O2  used (2 mM). 
Endothelial cell would not likely encounter such a massive stress in vivo. H2O2 and its metabolite, the 
hydroxyl radical, contribute to the pathogenesis of reperfusion injury in many organ systems and cell 
types [17]. H2O2 is widely used in vitro as it easily penetrates the cell membrane and causes 
intracellular injury. Our preliminary studies showed that H2O2-induced necrosis in EA.hy926 cells is Int. J. Mol. Sci. 2012, 13 986 
 
dose- and time-dependent. We chose to utilize 2 mM H2O2 as preliminary experiments demonstrated 
that these doses killed endothelial cells rapidly (within 4–8 hours). Lower doses (~0.5–2 mM) killed 
cells more slowly (>6 hours). Previous studies, including the ones from our laboratory, suggest 
immortalized cells in vitro require higher concentrations of oxidant stress for induction of necrosis [17].  
In this study, we demonstrate that isoflurane induces phosphorylation of ERK MAPK and induces 
SK1 mRNA, protein and activity in human endothelial cells. We propose that activation of endothelial 
SK1 and ERK MAPK mediates the anti-apoptotic effects of isoflurane against TNF-αinduced 
apoptosis in EA.hy926 cells. We previously showed that isoflurane externalized plasma membrane 
phosphatidylserine with subsequent release of TGF-β1 [5]. We also demonstrated that volatile 
anesthetics phosphorylated ERK MAPK via TGF-β1 signaling in human proximal tubule epithelial 
cells and this ERK MAPK activation was directly responsible for the protective effects of volatile 
anesthetics in the kidney [5]. Furthermore, we previously showed that isoflurane induced expression 
and activity of SK1 in human proximal tubule cells [13] as well as human intestinal epithelial cells [18] 
that was directly responsible for isoflurane-mediated kidney and intestine protection, respectively. In 
above studies, blockade of SK1 with a selective inhibitor (SKI-II, 4-[[4-(4-Chlorophenyl)-2-
thiazolyl]amino]phenol) or deletion of SK1 (with SK1 KO mice) abolished the protective effects of 
isoflurane treatment [12]. Other studies have implicated the upregulation of S1P by isoflurane as the 
mode of protection from hypoxic-ischemic brain injury in rats [10].  
Volatile anesthetics are powerful modulators of plasma membrane lipid biochemistry including 
sphingolipid metabolism [6]. Once administered, volatile anesthetics rapidly interact with vascular 
endothelium, which is a potent contributor of plasma S1P [19]. Sphingolipids and their metabolites 
have been shown to play roles in various physiologic and pathophysiologic pathways [20]. SK has two 
mammalian isoforms, SK1 and SK2, which catalyze the ATP-dependant phosphorylation of sphingosine to 
S1P [21]. SK1 is found in the cytosol of eukaryotic cells, and when activated translocates to the 
plasma membrane. SK2 is found in the nucleus and endoplasmic reticulum and its function is less well 
known. The phosphorylation product of sphingosine kinase, S1P, promotes cell growth and differentiation 
and is a powerful anti-apoptotic ligand for specific G protein coupled S1P receptors [7,22]. It is well 
documented that S1P produces anti-apoptotic effects in various cell types [13,23,24]. Activation of 
S1P receptors has been shown to protect against ischemia reperfusion injury in the heart [25],   
liver [26] and kidney [27]. Furthermore, ERK MAPK is a component of the MEK1/MAPK/Ras 
pathway which governs proliferation, differentiation, and cell survival [28]. Indeed, SK-1 and S1P has 
been shown to upregulate the ERK MAPK pathway as the mechanism for increasing cell survival [29]. 
While several previous studies demonstrate tissue-protective effects of several clinically utilized 
volatile anesthetics [11,12,25,29,30], there are studies that show detrimental and cytotoxic effects of 
volatile anesthetics. In particular, volatile anesthetics have been shown to produce detrimental 
neuronapoptotic effects in the developing brain of rats and mice [31,32]. Volatile anesthetics reduce 
dendritic branching and synaptogenesis [33–35], cause apoptotic neuron-degeneration in the 
developing hippocampus and neocortex [32] and cognitive dysfunction in rats [36]. It is hard to 
reconcile the differences of these findings to our study. Perhaps short term exposure to volatile 
anesthetics in an adult cell line results in cytoprotection whereas relative long exposure in neonatal 
tissue may produce detrimental effects. Indeed, there are studies that demonstrate neuroprotective 
effects of clinically used volatile anesthetics. In the setting of cerebral ischemia, isoflurane Int. J. Mol. Sci. 2012, 13 987 
 
pretreatment improves cerebral blood flow [37] and benefits both short and long neurological   
outcome [38] in rats. It has also been shown to be neuroprotective in the setting of traumatic brain 
injury [39,40]. 
3. Experimental Section 
3.1. Cell Culture 
Immortalized human umbilical vein endothelial cell line (EA.hy926, purchased from American 
Type Culture Collection, Manassas, VA, USA) were grown and passaged in culture medium 
(Dulbecco’s modified Eagle’s medium + 10% fetal bovine serum) at 37 °C in a 95% room air + 5% 
CO2 humidified environment. This cell line has been characterized extensively and retains physiologic 
and functional characteristics of endothelial cells [41]. 
3.2. Exposure of EA.hy926 Cells to Isoflurane 
EA.hy926 cells were exposed to isoflurane (2-Chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane, 
Abbott Laboratories, Chicago, IL, USA) as described previously [5]. In brief, EA.hy926 cells were 
placed in an air-tight, 37 °C, humidified modular incubator chamber (Billups-Rothenberg, Del Mar, 
CA, USA) and exposed to 2.5% (2 MAC) isoflurane (where 1 MAC is defined as the percent 
concentration in the alveolus of an inhaled anesthetic agent required to prevent 50% of subjects from 
moving in response to a painful stimulus when used as the sole anesthetic) mixed with 95% air + 5% 
CO2 (carrier gas). Exposure to isoflurane was between 4 to 16 hours. We have previously 
demonstrated that clinically relevant concentrations of volatile anesthetics (0.5–2 MAC) produce 
cytoprotective signaling in human proximal tubule (HK2) cells [5], and used a similar protocol. 
Control cells were exposed to carrier gas in an identical modular incubator for the same duration. 
3.3. Induction of EA.hy926 Cell Necrosis with Hydrogen Peroxide (H2O2) 
After pretreatment (16 hours) with isoflurane or with carrier gas, EA.hy926 cells were exposed to 
oxidative stress necrosis with 2 mM H2O2 in the 37 °C modular incubator exposed to 95% air + 5% CO2 
for 2–24 hours. After exposure, culture media was collected and assayed for lactate dehydrogenase 
(LDH) released from necrotic cells. We previously demonstrated that this dose of H2O2 causes 
significant necrosis without appreciable apoptosis in cell culture [5]. 
3.4. Induction of EA.hy926 Cell Apoptosis Using Tumor Necrosis Factor-α (TNF-α) 
To induce apoptosis, EA.hy926 cells were exposed to TNF-α (20 ng/mL) in the 37 °C modular 
incubator exposed to 95% air + 5% CO2 for 48 hours after 16 hours of pretreatment with 2 MAC 
isoflurane or with carrier gas. This dose was determined in preliminary experiments to produce 
consistent inflammatory changes in cell culture (data not shown). Int. J. Mol. Sci. 2012, 13 988 
 
3.5. Detection of Apoptosis 
We used 2 independent techniques to detect apoptosis in EA.hy926 cells 1) with in situ Terminal 
Deoxynucleotidyl Transferase Biotin-dUTP Nick-End Labeling (TUNEL) Assay and 2) with DNA 
laddering assay. In situ labeling of fragmented DNA was performed with TUNEL (green fluorescence) 
with a commercially available in situ cell death detection kit (Roche, Nutley, NJ, USA) according to 
the manufacturer's instructions. To visualize the total number of cells in the field, slides were also 
stained with propidium iodide (red fluorescence). The slides were evaluated blindly through the 
counting of the labeled cells in 200× magnified fields.  
For DNA laddering assay, DNA fragments isolated from EA.hy926 cells were extracted according 
to the methods of Herrmann et al. [42] and was electrophoresed at 70 V in a 2.0% agarose gel in  
Tris-acetate-EDTA buffer. This method of DNA extraction selectively isolates apoptotic, fragmented 
DNA and leaves behind majority of intact chromatin. The gel was stained with ethidium bromide and 
photographed under UV illumination. DNA ladder markers (100 bp) were added to a lane of each gel 
as a reference for the analysis of internucleosomal DNA fragmentation. 
3.6. Detection of necrosis with LDH Measurement 
LDH released into cell culture media as an indicator of rapid cell lysis from necrosis was measured 
with an LDH assay kit (Promega, Madison, WI, USA). LDH released into the media is expressed as 
percentage of total cellular LDH measured after cells are lysed with 1% Triton X-100. 
3.7. Immunoblot Analysis 
After exposure to carrier gas or isoflurane, EA.hy926 cells were probed for SK1, sphingosine 
kinase-2 (SK2) and phosphorylated or total ERK MAPK by immunoblot analysis as previously 
described [43]. In brief, EA.hy926 cells were lysed with ice cold RIPA buffer [150 mM NaCl, 50 mM 
Tris-HCl, 1 mM EDTA, and 1% Triton-X (pH 7.4)] with phosphatase and protease inhibitors. Ten to 
50 μg of EA.hy926 lysates were electrophoresed on a 10% polyacrylamide gel and transferred to a 
PVDF membrane. Primary antibodies for SK1 (1:1000 dilution) were purchased from Cell Signaling 
Technologies (Danvers, MA, USA). Primary antibodies for SK2 (1:1000) were purchased from Abcam 
(Cambridge, MA, USA). Primary antibodies for β-actin (1:5000) were purchased from Sigma   
(St. Louis, MO, USA). Primary antibodies for phosphorylated ERK (1:1000) and total ERK MAPK 
(1:1000) were purchased from Santa Cruz biotechnology (Santa Cruz, CA, USA). As phosphorylation 
products are synthesized quicker, when blotting for ERK MAPK isoflurane exposure was limited to  
4 hours. We have previously determined that 16 hour volatile anesthetic exposure was optimal to 
capture sphingosine kinase expression. Secondary antibody [sheep anti-mouse or donkey anti-rabbit 
igG conjugated to horseradish peroxidase at 1:5000 dilution (GE Healthcare, Piscataway, NY, USA)]  
was detected with enhanced chemiluminescence immunoblotting detection reagents (Amersham, 
Piscataway, NJ, USA) with subsequent exposure to a CCD camera coupled to a UVP Bioimaging 
System (Upland, CA, USA) and a personal computer. Int. J. Mol. Sci. 2012, 13 989 
 
3.8. Semi-Quantitative Reverse Transcription–Polymerase Chain Reaction (RTPCR) 
After exposure to carrier gas or isoflurane, we detected mRNA expression of SK1 and SK2 as 
previously described using the Access RT-PCR System (Promega) [43]. The quantitative accuracy of 
our RT-PCR technique was first confirmed for each primer pair used. The PCR cycle number for each 
primer pair was optimized for linear increases in densitometric band intensity measurements with 
increasing PCR cycles from 15–26. The starting amount of RNA (0.25–1 μg) was also optimized for 
linear increase in densitometric band intensity measurements at an optimized cycle of PCR. SK1 and 
SK2 primers were designed based on published GenBank sequences for human (Table 1) and to 
amplify a genomic region that spans one or more introns to distinguish mRNA products from genomic 
DNA contamination. Semiquantitative RT-PCR was done under conditions yielding linear results for 
GAPDH to confirm equal RNA input. Five microliters of the RT-PCR product were analyzed on a 6% 
acrylamide gel stained with SYBR green (Invitrogen, Carlsbad, CA, USA) for analysis with a UVP 
Bioimaging System. 
Table 1. Primers used to amplify mRNAs encoding murine SK1, SK2, and GAPDH based 
on published GenBank sequences for mice. 
Primers Accession 
Number 
Sequence (Sense/Antisense  Product 
Size (bp) 
Cycle 
Number 
Annealing 
Temp. (°C) 
Human SK1  NM_021972  5'-ATCTCCTTCACGCTGATGC-3' 
5'-GTGCAGAGACAGCAGGTTCA-3' 
330 26  66 
Human SK2  NM_020126  5'-GGAGGAAGCTGTGAAGATGC-3' 
5'-GCAGGTCAGACACAGAACGA-3' 
482 22  66 
Human 
GAPDH 
NM_002046 5'-ACCACAGTCCATGCCATCAC-3' 
5'-CACCACCCTGTTGCTGTAGCC-3' 
450 15  65 
SK = sphingosine kinase; GAPDH = glyceraldehyde 3-phosphate dehydrogenase; Respective anticipated   
RT-PCR product size, PCR cycle number for linear amplification and annealing temperatures used for each 
primer are also provided. 
3.9. SK Activity Assay 
SK activity was measured as described by Vessey et al. [44] with some modifications as   
described [12]. 
3.10. High-Pressure Liquid Chromatography (HPLC) Detection of S1P 
Confluent EA.hy926 cells were sonicated in PBS (pH 7.2). Aliquots were used for protein assay 
and the remainder of EA.hy926 cellular lysates were processed by HPLC to measure S1P levels as 
described by Min et al. [45] with two steps of sample pretreatment: enzymatic dephosphorylation of 
S1P by alkaline phosphatase (100 U/sample, Sigma) and subsequent analysis of ophthalaldehyde 
derivatives of the liberated sphingosine bases by HPLC. By introducing C17 S1P (Avanti Polar Lipids, 
Inc., Alabaster, AL) as an internal standard, S1P present in a sample can be quantified on a C18 
reversed-phase column with a simple mobile phase of acetonitrile:deionized distilled water (89:11, 
v/v) and expressed as fold increase over the carrier gas-treated group. Int. J. Mol. Sci. 2012, 13 990 
 
3.11. Statistical Analysis 
The data were analyzed with t-test when means between two groups were compared or with   
one-way ANOVA plus Tukey post hoc multiple comparison test to compare mean values across 
multiple treatment groups. In all cases, p < 0.05 was taken to indicate significance. All data are 
expressed as mean ± SEM.  
3.12. Reagents and Protein Determination 
Unless otherwise specified, all chemicals were obtained from Sigma. Protein contents were 
determined with a bicinchoninic acid protein assay kit (Pierce Chemical Co., Rockford, IL), using 
bovine serum albumin as a standard. 
4. Conclusion 
We demonstrate in this study that a clinically used volatile anesthetic (isoflurane) reduces apoptosis 
in human endothelial cells, presumably via ERK MAPK phosphorylation, SK1 induction and increased 
S1P synthesis. In vivo studies will be required to translate our in vitro findings. Further elucidation of 
the mechanisms of protection may lead to advancements in the treatment of diverse human diseases 
involving endothelial dysfunction. 
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